PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Seiz, L.* ; Dorn, J.* ; Kotzsch, M.* ; Walch, A.K. ; Grebenchtchikov, N.I.* ; Gkazepis, A.* ; Schmalfeldt, B.* ; Kiechle, M.* ; Bayani, J.* ; Diamandis, E.P.* ; Langer, R.* ; Sweep, F.C.* ; Schmitt, M.* ; Magdolen, V.*

Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients.

Biol. Chem. 393, 391-401 (2012)
DOI PMC
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
Several members of the human kallikrein-related peptidase family, including KLK6, are up-regulated in ovarian cancer. High KLK6 mRNA or protein expression, measured by quantitative polymerase chain reaction and enzyme-linked immunoassay, respectively, was previously found to be associated with a shortened overall and progression-free survival (OS and PFS, respectively). In the present study, we aimed at analyzing KLK6 protein expression in ovarian cancer tissue by immunohistochemistry. Using a newly developed mono-specific polyclonal antibody, KLK6 immunoexpression was initially evaluated in normal tissues. We observed strong staining in the brain and moderate staining in the kidney, liver, and ovary, whereas the pancreas and the skeletal muscle were unreactive, which is in line with previously published results. Next, both tumor cell- and stromal cell-associated KLK6 immunoexpression were analyzed in tumor tissue specimens of 118 ovarian cancer patients. In multivariate Cox regression analysis, only stromal cell-associated expression, besides the established clinical parameters FIGO stage and residual tumor mass, was found to be statistically significant for OS and PFS [high vs. low KLK6 expression; hazard ratio (HR), 1.92; p=0.017; HR, 1.80; p=0.042, respectively]. These results indicate that KLK6 expressed by stromal cells may considerably contribute to the aggressiveness of ovarian cancer.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.965
0.779
32
36
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cancer Biomarker ; Immunohistochemistry ; Kallikrein-related Peptidase 6 ; Klk6 ; Ovarian Cancer ; Prognosis; HUMAN TISSUE KALLIKREINS; CENTRAL-NERVOUS-SYSTEM; ACTIVATION PROFILES; BREAST-CANCER; GENE FAMILY; CARCINOMA; PROTEIN; SPECIFICITY; INHIBITORS; BIOMARKER
Sprache
Veröffentlichungsjahr 2012
HGF-Berichtsjahr 2012
ISSN (print) / ISBN 1431-6730
e-ISSN 1437-4315
Zeitschrift Biological Chemistry
Quellenangaben Band: 393, Heft: 5, Seiten: 391-401 Artikelnummer: , Supplement: ,
Verlag de Gruyter
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Analytical Pathology (AAP)
Institute of Pathology (PATH)
POF Topic(s) 30205 - Bioengineering and Digital Health
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-500390-001
G-500300-001
PubMed ID 22505521
DOI 10.1515/hsz-2011-0264
WOS ID WOS:000304334100009
Scopus ID 84859827944
Erfassungsdatum 2012-06-14
[➜Korrektur melden]